Kuangli Bio-Tech Holdings Co (TPE:6431) Research & Development: NT$33.3 Mil (TTM As of Dec. 2025)


TPE:6431 Kuangli Bio-Tech Holdings Co Ltd TPE:6431
66 GF Score
Price NT$18.20
GF Value NT$11.76
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Kuangli Bio-Tech Holdings Co Research & Development?

Kuangli Bio-Tech Holdings Co TPE:6431 -0.27% 66 Research & Development is NT$33.3 Mil as of Dec. 2025. GuruFocus rates TPE:6431 with a GF Score™ of 66/100 and a GF Value™ of NT$11.76 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Kuangli Bio-Tech Holdings Co's Research & Development for the three months ended in Dec. 2025 was NT$6.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$33.3 Mil.

Kuangli Bio-Tech Holdings Co  (TPE:6431) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kuangli Bio-Tech Holdings Co Research & Development Related Terms

Kuangli Bio-Tech Holdings Co Research & Development Historical Data

* Premium members only.

The historical data trend for Kuangli Bio-Tech Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuangli Bio-Tech Holdings Co Research & Development Chart

Kuangli Bio-Tech Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.05 32.27 30.80 32.25 33.27

Kuangli Bio-Tech Holdings Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.18 8.86 9.87 8.12 6.42
TPE:6431
66GF Score
Kuangli Bio-Tech Holdings Co Ltd TPE:6431
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuangli Bio-Tech Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$33.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$33.3 Mil mean?
Kuangli Bio-Tech Holdings Co (TPE:6431) has a Research & Development of NT$33.3 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Kuangli Bio-Tech Holdings Co and its competitors.
Is Kuangli Bio-Tech Holdings Co's Research & Development too high?
Kuangli Bio-Tech Holdings Co's current Research & Development is NT$33.3 Mil. Overall, Kuangli Bio-Tech Holdings Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kuangli Bio-Tech Holdings Co's Research & Development compare to PG and CL?
Kuangli Bio-Tech Holdings Co's Research & Development of NT$33.3 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kuangli Bio-Tech Holdings Co and its competitors. Kuangli Bio-Tech Holdings Co's current Research & Development is NT$33.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuangli Bio-Tech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co (TPE:6431) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$11.76, compared to a current price of NT$18.20 — trading 54.8% above its estimated fair value. The current Research & Development is NT$33.3 Mil. Kuangli Bio-Tech Holdings Co's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kuangli Bio-Tech Holdings Co (TPE:6431), the current Research & Development is NT$33.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuangli Bio-Tech Holdings Co (TPE:6431) Overvalued in 2026?

Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co stock appears to be overvalued. The current stock price of NT$18.20 is trading 54.8% above its estimated GF Value™ of NT$11.76. GuruFocus considers Kuangli Bio-Tech Holdings Co to be Significantly Overvalued.

Key valuation signals for TPE:6431:

  • Research & Development: NT$33.3 Mil
  • GF Value™: NT$11.76 vs. price of NT$18.20 (54.8% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the TPE:6431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuangli Bio-Tech Holdings Co Business Description

Address North Sound Road, Suite 102, Cannon Place, George Town, Grand Cayman, CYM
Kuangli Bio-Tech Holdings Co Ltd is mainly engaged in the manufacture and trading of various types of panels (LENS), such as mobile phone panels, digital camera windows, PDA panels, and instrument panels. The company is also engaged in the development, manufacturing and trading of cosmetics and skin care products and other related biotechnology products. It derives revenue from Health and Wellness products, and Cosmetics and skin care products, including Lotion, Facial masks, and Other pastes. The primary source of revenue for the company is sales of cosmetic products.
66GF Score

Get the complete analysis for TPE:6431

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.20
Price
NT$11.76
GF Value